Bortezomib and dexamethasone, an original approach for treating multi‐refractory warm autoimmune haemolytic anaemia. (2nd June 2019)

• Record Type: Journal Article
• Authors: Fadlallah, Jehane; Michel, Marc; Crickx, Etienne; Limal, Nicolas; Costedoat, Nathalie; Malphettes, Marion; Fieschi, Claire; Galicier, Lionel; Oksenhendler, Eric; Godeau, Bertrand; Audia, Sylvain; Mahévas, Matthieu
• Is Part Of: British journal of haematology. Volume 187:Number 1(2019)
• Page Start: 124
• Page End: 128
• Publication Date: 2019-06-02
• Subjects: auto‐immune haemolytic anaemia -- refractory -- bortezomib; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16009
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: We report the off‐label use of bortezomib combined with dexamethasone in eight adults with severe and multi‐refractory warm auto‐immune haemolytic anaemia (wAIHA). After six cycles of induction therapy, 6 of the 8 patients achieved response (3 complete response, 3 response). Response was obtained after a median of 2 (1–4) cycles. After a median follow‐up of 14 (6–36) months, six patients maintained a response (bortezomib/dexamethasone maintenance, n = 4); five patients experienced at least one moderate adverse event, including peripheral neuropathy ( n = 2). These results suggest that bortezomib/dexamethasone combination is a promising approach with acceptable toxicity for treating severe refractory wAIHA in adults.